Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.39 |
| ▸ | JMJD6 | Q6NYC1 | 5/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20912234 | 0.84 | SCN4A (0.41) | KMT2AMAPK10JMJD6KEAP1SCN4A | |
| SCHEMBL19480882 | 0.83 | CYP2A6 (0.46) | KMT2AMAPK10JMJD6CCR1CCR5 | |
| SCHEMBL20912063 | 0.75 | TGFBR1 (0.41) | KMT2AMAPK10JMJD6KEAP1CYP19A1 | |
| SCHEMBL15885475 | 0.73 | CASP6 (0.47) | KMT2AJMJD6KEAP1SCN4ACASP6 | |
| SCHEMBL19480879 | 0.72 | KEAP1 (0.43) | KMT2AMAPK10JMJD6KEAP1CYP19A1 | |
| SCHEMBL42126 | 0.72 | CCR1 (0.64) | KMT2AJMJD6CCR1CCR5CCR8 | |
| SCHEMBL3448871 | 0.70 | KMT2A (0.42) | KMT2AJMJD6KEAP1S1PR2 | |
| SCHEMBL20912237 | 0.70 | NNMT (0.43) | KMT2AJMJD6S1PR2 | |
| SCHEMBL13744209 | 0.69 | MKNK1 (0.54) | KMT2AKEAP1SCN4ACYP19A1 | |
| SCHEMBL31512002 | 0.69 | NOS3 (0.46) | KMT2AMAPK10JMJD6KEAP1S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112292-A1 | NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES | HCRTR2, HCRTR1, CNR2 | KMT2A 955/4885MAPK10 3537/4885JMJD6 2694/4885 |
| US-10738031-B2 | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity | HCRTR2, HCRTR1, CNR1 | KMT2A 1113/4885MAPK10 3844/4885JMJD6 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.